Download the comprehensive report now. Explore Clinical Stage Development and Strategic CollaborationsChange the industry! Lyme Disease Pipeline Outlook Report

Key Takeaways from the Lyme Disease Pipeline Report

• December 2024、 Moderna TX Inc. We have started a Phase 1/2 randomized, observer-blinded, placebo-controlled, dose-ranging studyRateSafety and immunogenicity of Heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) vaccines against Lyme disease in healthy elderly participants18-70 years old。
• DelveInsight Lyme Disease Pipeline Report: Present Robust Landscape, and 7 or more active players. Development 7+ Pipeline Therapies for Treatment of Lyme Disease。
• Lyme Disease Big Players include Valneva、Cortene、Blue Lake Biotechnology、Tarsus Pharmaceuticals、Inovio Pharmaceuticals、Aegis Life、Abzyme Therapeutics, And more.
• Promising Lyme Disease Treatment. Like VLA15, mRNA-1975, low-dose TP-05, and others are in development.

Learn how leading Lyme disease companies are positioning themselves for success in the evolving pharmaceutical market.—Access the full report now! @ Evaluation of Lyme Disease Clinical Trials

Emerging Treatments for Lyme Disease

VLA15: Valneva

• VLA15CurrentlyThe only active vaccine program in Clinical development against Lyme disease。
• VLA15 is a Multivalent Recombinant Protein vaccine targeting six serotypes of Borrelia, representing the most common pathogenic strains United States and Europe。
• Valneva has completed its recruitment and reported early recruitment results for two Phase 2 clinical trialsGet InvolvedOver 800 healthy adults, indicating High levels of antibodies everythingSix serotypes.
• Valneva Announces Partnership with Pfizer for Late-Stage Development and Commercial Potential of VLA15.

CT38: Corten

• CT38 is a Potent, short-lived peptide agonist selective for CRFR2, fully configured Naturally Occurring Amino Acids.
• CT38 Tested on animals and Healthy humans in Phase 1 Clinical Trials, its definition Safety Profile for humans.
• According to the study, CT38 only lasts in the body for a few hours.

The Lyme Disease Pipeline Report Offers the Following Insights:

• Companies developing treatments for Lyme disease and Group therapy are developed by each company.
• Various treatment candidates are classified as follows. Early, mid, and late development forthe  Treatment of Lyme Disease。
• Lyme Disease Companies Involved in Targeted drug development, including Active and inactive (dormant or discontinued) projects.
• Treatment for Lyme disease development, categorized based on stage of development, route of administration, target receptor, monotherapy or combination therapy, mechanism of action, and type of molecule.
• Detailed Analysis of Collaboration (company-to-company, company-to-academia)、 License Agreement, and Financing Details for Future Progress of Lyme Disease Market.

Don't miss out, download it now and stay up to date. @ Lyme disease medication

Lyme Disease Companies

Valneva, Cortene, Blue Lake Biotechnology, Tarsus Pharmaceuticals, Inovio Pharmaceuticals, Aegis Life, Abzyme Therapeutics, others.

The Lyme disease pipeline report provides treatment assessment (ROA) by route of administration.

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Hot Topic

Lyme disease products categorized by molecular type:

• Monoclonal antibodies
• peptide
• polymer
• Low molecular weight
• Gene Therapy

Stay up to date with insights into the latest Lyme disease pipeline. Download the report to take a closer look at next-generation treatments. @ Lyme Disease Market Drivers, Barriers, and Future Outlook

Lyme Disease Pipeline Report Scope

• coverage: global
• Lyme Disease Companies: Valneva、Cortene、Blue Lake Biotechnology、Tarsus Pharmaceuticals、Inovio Pharmaceuticals、Aegis Life、Abzyme Therapeutics など。
• Lyme Disease Treatment: VLA15, mRNA-1975, low-dose TP-05, etc.
• Lyme Disease Treatment Rating by Product Type: Mono, Combination, Mono/Combination
• Lyme disease treatment assessment by clinical stage: Discovery, Preclinical, Phase I, Phase II, Phase III

Find the answers in our latest Lyme Disease Pipeline Insights report, which offers in-depth coverage of clinical trials, regulatory developments, and upcoming breakthroughs. Download it now and stay at the forefront of pharmaceutical innovation!" @Emerging Lyme Disease Drugs and Companies

table of contents

• introduction

• executive summary

• Lyme Disease: An Overview

• Pipeline Therapeutics

• Therapeutic evaluation

• Lyme Disease – A DelveInsight Perspective

• Late Stage Products (Phase III)

• VLA 15: Valneva

• Drug profile in detailed report…..

• Early Stage Products (Phase I)

• CT 38: Corten

• Drug profile in detailed report…..

• Preclinical and Discovery Stage Products

• Lyme Disease Vaccine - Introvacc

• Drug profile in detailed report…..

• Inactive Products

• Lyme Disease Major Companies

• Lyme Disease Main Products

• Lyme Disease – An Unmet Need

• Lyme Disease-Market Drivers and Barriers

• Lyme Disease - Future Outlook and Conclusions

• Lyme Disease Analyst's Viewpoint

• Lyme Disease Major Companies

• appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm, providing clients with high-quality market intelligence and analytics to support informed business decisions. With an experienced team of industry experts and a deep understanding of the life sciences and healthcare sector, we deliver customized research solutions and insights to clients globally. Contact us to get high-quality, accurate, real-time intelligence to stay ahead of the growth curve.

Contact Information:

Himanshu

hmason@delveinsight.com

info@delveinsight.com

+14699457679